1. HOME
2. Research Insight
3. Bio-Rad Laboratories, Inc. (US) and QuidelOrtho Corporation (US) are Leading Players in the Blood Group Typing Market

The blood group typing market is valued at an estimated USD 2.0 billion in 2023 and is projected to reach USD 3.0 billion by 2028 at a CAGR of 8.7% during the forecast period. Market growth is largely driven by the increasing prevalence of chronic diseases and the rising number of surgical procedures necessitating the need for blood donations.

The key players in this market are Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), Grifols, S.A. (Spain), Thermo Fisher Scientific Inc. (US), Immucor, Inc. (US), Danaher (US), Merck KGaA (Germany), Quotient Limited (Switzerland), Novacyt (France), BAG Health Care GmbH (Germany), Rapid Labs Ltd (UK), Agena Bioscience, Inc. (US), Biorex Diagnostics (UK), HUMAN Gesellschaft für Biochemica und Diagnostica mbH (Germany), Prestige Diagnostics (UK), Span Diagnostics SARL (France), DIALAB GmbH (Austria), Lorne Laboratories Limited (UK), Atlas Medical GmbH (Germany), Torax Biosciences Limited (Northern Ireland), Fortress Diagnostics (UK), AXO Science (France), Maxwin Health Care Pvt. Ltd. (India), Anamol Laboratories Pvt. Ltd. (India), J. Mitra & Co. Pvt. Ltd. (India), and MedSource Ozone Biomedicals Pvt. Ltd. (India).

To know about the assumptions considered for the study download the pdf brochure

Bio-Rad Laboratories, Inc. (US) maintained its dominant position in the blood group typing market in 2022. The company’s strong distribution networks spanning North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa have contributed to its sustained leadership in the market. The company employs organic and inorganic growth strategies to enhance its market dominance, such as product launches and agreements. In May 2023, the company launched the IH-500TM NEXT System, a fully automated system for ID cards. The IH-500 NEXT System not only reduces instrument downtime and increases laboratory productivity but also provides the flexibility and freedom to use high-performing Bio-Rad Reagent Red Blood Cells (RBCs), as well as the lab’s own RBCs or third-party Reagent RBCs. In line with this, in October 2022, Bio-Rad successfully installed its IH-500 systems across the SANBS network of 86 labs and blood banks, enabling high-quality and consistent lab testing across the provinces that rely on SANBS to provide blood products and services to South Africa’s citizens, as part of an exclusive agreement finalized in early 2022. These strategic initiatives enable Bio-Rad to secure a larger market share and strengthen its position in the blood group typing market.

In 2022, QuidelOrtho Corporation (US) held a significant market share in the blood group typing market. The company’s leading position can be attributed to its robust global sales and distribution network, which effectively promotes its products across various countries. QuidelOrtho has strategically emphasized research & development (R&D) initiatives to develop innovative and superior offerings compared to its competitors. By investing in R&D, the company aims to optimize its product portfolio and allocate capital wisely, thereby fostering future growth and maintaining its competitiveness in the Transfusion Medicine segment.

Furthermore, QuidelOrtho implements both organic and inorganic strategies, such as regulatory approvals and acquisitions, to further strengthen its standing in the blood group typing market. In March 2021, the company received US FDA approval for its ORTHO Optix Reader. This strategic move expanded the company’s product line considerably and enhanced its market visibility, bolstering its overall position in the industry. In March 2022, Quidel Corporation acquired Ortho Clinical Diagnostics. This acquisition aims to unite technologies and platforms from both companies in order to offer expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostic offerings.

Grifols, S.A. (Spain), a prominent player in the global blood group typing market, secured a significant market share in the blood group typing market in 2022. The company’s strong presence in the US and Canada serves as a foundation for expanding its operations in emerging markets, thereby strengthening its geographical reach. Grifols caters to a diverse customer base across various geographic locations by continuously developing new products. In addition to its R&D efforts and supply chain management, Grifols leverages inorganic growth strategies to maintain its market leadership. For example, in July 2021, Grifols reaffirmed its commitment to expanding its plasma supply to meet the growing demand for plasma therapies. It will develop 21 additional plasma collection centers in the US in collaboration with ImmunoTek. Such developments contribute to Grifols’ continued success and its sustained leading position in the blood group typing market.

Related Reports:

Blood Group Typing Market by Product (Consumables, Instruments, Services), Test Type (ABO, Antigen, Antibody, HLA), Technique (Assay-based, PCR, Microarray, Massively Parallel Sequencing), End User (Hospital, Blood Banks), Region - Global Forecast to 2028

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]